Allegro continues studies of integrin peptide therapy

Allegro Ophthalmics has completed enrollment of a phase 1b/2a study of the impact of its integrin peptide therapy on wet age-related macular degeneration, according to a company news release. In addition, Allegro has begun a second study of the therapy’s impact on diabetic macular edema.Safety is the primary endpoint of the dose-ranging, monotherapy wet AMD study of ALG-1001, with secondary endpoints of improvement in central macular thickness and best corrected visual acuity.

Full Story →